Carazolol: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Drugbox| | {{Drugbox| | ||
|IUPAC_name = 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol | |IUPAC_name = 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol | ||
| Line 21: | Line 20: | ||
| routes_of_administration= | | routes_of_administration= | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Carazolol''' is a high affinity [[antagonist]]/partial inverse agonist (also referred to as a [[beta blocker]]) of the β-[[adrenergic receptor]].<ref name="pmid41147">{{cite journal | author = Innis RB, Corrēa FM, Synder SH | title = Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes | journal = Life Sci. | volume = 24 | issue = 24 | pages = 2255–64 | year = 1979 | pmid = 41147 | doi = | issn = }}</ref> | '''Carazolol''' is a high affinity [[antagonist]]/partial inverse agonist (also referred to as a [[beta blocker]]) of the β-[[adrenergic receptor]].<ref name="pmid41147">{{cite journal | author = Innis RB, Corrēa FM, Synder SH | title = Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes | journal = Life Sci. | volume = 24 | issue = 24 | pages = 2255–64 | year = 1979 | pmid = 41147 | doi = | issn = }}</ref> | ||
==External links== | ==External links== | ||
* {{MeshName|Carazolol}} | * {{MeshName|Carazolol}} | ||
==References== | |||
{{reflist|2}} | |||
{{Beta blockers}} | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
[[Category:Beta blockers]] | |||
Revision as of 02:54, 25 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C18H22N2O3 |
| Molar mass | 298.38 |
|
WikiDoc Resources for Carazolol |
|
Articles |
|---|
|
Most recent articles on Carazolol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Carazolol at Clinical Trials.gov Clinical Trials on Carazolol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Carazolol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Carazolol Discussion groups on Carazolol Directions to Hospitals Treating Carazolol Risk calculators and risk factors for Carazolol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Carazolol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Carazolol is a high affinity antagonist/partial inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.[1]
External links
- Carazolol at the US National Library of Medicine Medical Subject Headings (MeSH)
References
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cardiovascular Drugs
- Drug
- Beta blockers